Capital One National Association Has Lifted Cullen Frost Bankers (CFR) Position By $1.89 Million; Last Week The Medicines Company (MDCO) Analysts

May 21, 2018 - By mmahotstuff

Cullen/Frost Bankers, Inc. (NYSE:CFR) Logo

Capital One National Association increased Cullen Frost Bankers Inc (CFR) stake by 148.43% reported in 2017Q4 SEC filing. Capital One National Association acquired 20,098 shares as Cullen Frost Bankers Inc (CFR)’s stock rose 7.06%. The Capital One National Association holds 33,638 shares with $3.18 million value, up from 13,540 last quarter. Cullen Frost Bankers Inc now has $7.70 billion valuation. The stock increased 1.42% or $1.69 during the last trading session, reaching $120.61. About 233,684 shares traded. Cullen/Frost Bankers, Inc. (NYSE:CFR) has risen 22.62% since May 21, 2017 and is uptrending. It has outperformed by 11.07% the S&P500.

Among 11 analysts covering The Medicines Co (NASDAQ:MDCO), 11 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. The Medicines Co had 37 analyst reports since August 28, 2015 according to SRatingsIntel. The rating was maintained by RBC Capital Markets on Monday, August 31 with “Outperform”. Oppenheimer upgraded the shares of MDCO in report on Wednesday, November 29 to “Buy” rating. The rating was maintained by RBC Capital Markets with “Outperform” on Monday, November 16. The stock has “Hold” rating by Jefferies on Friday, August 28. The stock of The Medicines Company (NASDAQ:MDCO) earned “Buy” rating by Oppenheimer on Monday, January 15. The firm has “Outperform” rating given on Wednesday, November 16 by RBC Capital Markets. As per Thursday, March 22, the company rating was maintained by Oppenheimer. The firm earned “Buy” rating on Tuesday, August 29 by Cowen & Co. As per Monday, August 31, the company rating was maintained by Oppenheimer. Jefferies maintained the stock with “Buy” rating in Wednesday, August 2 report. See The Medicines Company (NASDAQ:MDCO) latest ratings:

22/03/2018 Broker: Oppenheimer Rating: Buy Maintain
22/02/2018 Broker: Oppenheimer Rating: Hold New Target: $50.0 Maintain
24/01/2018 Broker: J.P. Morgan Rating: Buy New Target: $45.0
22/01/2018 Broker: Citigroup Rating: Buy New Target: $40.0 Upgrade
15/01/2018 Broker: Oppenheimer Rating: Buy New Target: $50.0 Maintain
29/11/2017 Broker: Oppenheimer Rating: Buy New Target: $50.0 Upgrade

Since December 7, 2017, it had 1 insider buy, and 3 sales for $783,400 activity. The insider MEANWELL CLIVE sold 136,250 shares worth $3.71 million. The insider ESHELMAN FREDRIC N bought 200,000 shares worth $5.31 million. Another trade for 7,500 shares valued at $241,950 was sold by CROUSE WILLIAM. On Tuesday, January 16 the insider KESSLER ARMIN M sold $574,200.

More notable recent The Medicines Company (NASDAQ:MDCO) news were published by: Seekingalpha.com which released: “The Medicines (MDCO) Q1 2018 Results – Earnings Call Transcript” on April 25, 2018, also Fool.com with their article: “Alnylam Looks Forward” published on May 08, 2018, Streetinsider.com published: “Medicines Co. (MDCO) ORION-1 Phase II Study Shows Significant Reductions in Potentially Harmful Subtypes of Bad …” on May 07, 2018. More interesting news about The Medicines Company (NASDAQ:MDCO) were released by: Streetinsider.com and their article: “Einhorn’s Greenlight Capital Enters Office Depot (ODP), Abercrombie & Fitch (ANF) (more…) – 13F” published on May 15, 2018 as well as Businesswire.com‘s news article titled: “The Medicines Company Announces Inclisiran Data Showing Significant Reductions in Potentially Harmful Subtypes of …” with publication date: May 07, 2018.

The Medicines Company, a biopharmaceutical company, provides medicines for patients in acute and intensive care hospitals worldwide. The company has market cap of $2.35 billion. The firm markets Angiomax, an intravenous direct thrombin inhibitor used as an anticoagulant in combination with aspirin in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty, and for patients undergoing percutaneous coronary intervention; Ionsys, a fentanyl iontophoretic transdermal system for the short term management of acute postoperative pain for adults requiring opioid analgesia in the hospital. It currently has negative earnings. It also markets Minocin IV, an intravenous formulation of a tetracycline-class antibiotic used for the treatment of infections due to susceptible strains of designated gram-negative bacteria; and Orbactiv, an intravenous antibiotic used for the treatment of adult patients with acute bacterial skin and skin structure infections, or caused or suspected to be caused by susceptible isolates of designated gram-positive microorganisms.

Investors sentiment increased to 1.25 in Q4 2017. Its up 0.47, from 0.78 in 2017Q3. It is positive, as 26 investors sold The Medicines Company shares while 51 reduced holdings. 28 funds opened positions while 68 raised stakes. 89.44 million shares or 5.03% more from 85.15 million shares in 2017Q3 were reported. Us Natl Bank De stated it has 0% of its portfolio in The Medicines Company (NASDAQ:MDCO). Aperio Group Ltd Liability holds 0% of its portfolio in The Medicines Company (NASDAQ:MDCO) for 25,368 shares. California State Teachers Retirement System invested in 0.01% or 108,795 shares. 1,525 were accumulated by Envestnet Asset Management. Brown Advisory Incorporated holds 8,355 shares or 0% of its portfolio. University Of Notre Dame Du Lac has 1.77% invested in The Medicines Company (NASDAQ:MDCO) for 312,066 shares. Ls Invest Advsr Limited Liability Corporation holds 2,145 shares or 0% of its portfolio. Pacad Invest stated it has 0.04% of its portfolio in The Medicines Company (NASDAQ:MDCO). Gemmer Asset Mgmt Ltd Llc accumulated 0% or 92 shares. 60,000 are held by Iguana Health Mgmt. Prudential holds 0% in The Medicines Company (NASDAQ:MDCO) or 106,372 shares. Trexquant Investment Lp owns 23,340 shares. X Co Ltd Liability Co reported 651 shares or 0% of all its holdings. First Mercantile Trust Co has invested 0.02% in The Medicines Company (NASDAQ:MDCO). Principal Fin Gp, a Iowa-based fund reported 499,984 shares.

The stock decreased 0.09% or $0.03 during the last trading session, reaching $31.94. About 291,041 shares traded. The Medicines Company (NASDAQ:MDCO) has declined 34.73% since May 21, 2017 and is downtrending. It has underperformed by 46.28% the S&P500.

More notable recent Cullen/Frost Bankers, Inc. (NYSE:CFR) news were published by: Streetinsider.com which released: “Oil boom sets European shares for best weekly streak since 2014” on May 18, 2018, also Seekingalpha.com with their article: “Philip Morris International Is A Value Trap – Cramer’s Lightning Round (5/8/18)” published on May 09, 2018, Bizjournals.com published: “Frost Bank updates customers about cybersecurity breach” on May 15, 2018. More interesting news about Cullen/Frost Bankers, Inc. (NYSE:CFR) were released by: Globenewswire.com and their article: “Report: Developing Opportunities within HealthEquity, Chicago Rivet & Machine, NorthStar Realty Europe, Cullen/Frost …” published on April 24, 2018 as well as Streetinsider.com‘s news article titled: “European shares set to extend winning streak on oil surge, weak euro” with publication date: May 18, 2018.

Investors sentiment increased to 1.29 in 2017 Q4. Its up 0.15, from 1.14 in 2017Q3. It improved, as 18 investors sold CFR shares while 94 reduced holdings. 51 funds opened positions while 93 raised stakes. 50.25 million shares or 0.55% less from 50.53 million shares in 2017Q3 were reported. Wellington Management Gp Limited Liability Partnership invested 0.02% of its portfolio in Cullen/Frost Bankers, Inc. (NYSE:CFR). Comm National Bank reported 16,408 shares or 0.02% of all its holdings. Guggenheim Capital Llc, Illinois-based fund reported 83,422 shares. Capital Fund holds 0% or 2,600 shares. New York-based Brown Brothers Harriman Co has invested 0% in Cullen/Frost Bankers, Inc. (NYSE:CFR). Metropolitan Life Ins has 16,430 shares for 0.02% of their portfolio. Department Mb Financial Bank N A stated it has 42 shares or 0% of all its holdings. Old Mutual Customised Solutions (Proprietary) Ltd has 0.01% invested in Cullen/Frost Bankers, Inc. (NYSE:CFR). Quebec – Canada-based Montrusco Bolton has invested 0.32% in Cullen/Frost Bankers, Inc. (NYSE:CFR). Oregon Pub Employees Retirement Fund, Oregon-based fund reported 20,982 shares. Citigroup has invested 0% in Cullen/Frost Bankers, Inc. (NYSE:CFR). Lord Abbett And Co Ltd Limited Liability Company reported 0.04% stake. Gabelli Funds Ltd Liability stated it has 36,000 shares or 0.02% of all its holdings. Texan Capital Mngmt reported 1.02% in Cullen/Frost Bankers, Inc. (NYSE:CFR). Lathrop Investment Mngmt Corp has invested 4.01% of its portfolio in Cullen/Frost Bankers, Inc. (NYSE:CFR).

Since December 13, 2017, it had 4 insider buys, and 8 sales for $5.07 million activity. WESTON GRAHAM M bought $4.99M worth of stock or 43,342 shares. Alonzo Annette M had sold 4,500 shares worth $479,610. McKnight Gary C sold $2.55M worth of stock or 24,000 shares. The insider ALEXANDER R DENNY sold 3,000 shares worth $322,500. FROST PATRICK B also sold $1.38M worth of Cullen/Frost Bankers, Inc. (NYSE:CFR) on Tuesday, January 30. Wolfshohl Candace K also sold $664,930 worth of Cullen/Frost Bankers, Inc. (NYSE:CFR) on Wednesday, December 13. The insider Bracher Paul sold $990,194.

Among 18 analysts covering CullenFrost (NYSE:CFR), 4 have Buy rating, 1 Sell and 13 Hold. Therefore 22% are positive. CullenFrost had 81 analyst reports since July 30, 2015 according to SRatingsIntel. The stock of Cullen/Frost Bankers, Inc. (NYSE:CFR) earned “Hold” rating by Piper Jaffray on Friday, October 6. Wedbush downgraded Cullen/Frost Bankers, Inc. (NYSE:CFR) rating on Thursday, November 17. Wedbush has “Underperform” rating and $78 target. On Thursday, July 30 the stock rating was maintained by RBC Capital Markets with “Sector Perform”. On Friday, October 7 the stock rating was initiated by Wedbush with “Neutral”. On Thursday, October 27 the stock rating was maintained by RBC Capital Markets with “Sector Perform”. The firm has “Underperform” rating by Macquarie Research given on Wednesday, January 13. RBC Capital Markets maintained the shares of CFR in report on Thursday, January 25 with “Hold” rating. As per Thursday, January 25, the company rating was maintained by SunTrust. As per Monday, December 19, the company rating was upgraded by SunTrust. The stock of Cullen/Frost Bankers, Inc. (NYSE:CFR) has “Equal-Weight” rating given on Friday, April 27 by Barclays Capital.

The Medicines Company (NASDAQ:MDCO) Institutional Positions Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>